Heart failure is a clinical syndrome due to a structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood in order to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues.
Symptoms are caused by ventricular dysfunction secondary to abnormalities of the myocardium, pericardium, endocardium, valves, heart rhythm and conduction.
Chronic heart failure is a state where patient's signs and symptoms have been unchanged (stable) for at least a month but may decompensate suddenly or slowly when stable chronic heart failure deteriorates leading to hospitalization.
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Patients with methamphetamine-associated heart failure (HF) with reduced left ventricular (LV) ejection fraction (HFrEF) have a more severe disease compared with other HF patients, a study has found. But more importantly, quitting meth leads to an improvement in LV function with fewer hospital admissions, suggesting that meth-associated HFrEF may be reversed.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
Patients with heart failure with reduced ejection fraction (HFrEF) who achieve 100 percent guideline-recommended target dose (GRTD) for both angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) and β-blockers have a reduced risk of all-cause mortality and heart failure hospitalization (HHF), a recent study showed.
While the clinical risk factors for atrial fibrillation (AF) and its associated adverse outcomes are similar across ethnicities in Asia, AF is more common in some ethnic groups than the others, reveal the latest data from the ASIAN-HF* registry.
Patients with type 2 diabetes mellitus (T2DM) who are overweight or obese but have high cardiorespiratory fitness (CRF)* may have a reduced risk of heart failure (HF), according to a study presented at EPI Lifestyle 2020.
A novel, wearable heart failure (HF) patch accurately predicted worsening HF and impending rehospitalization days before the event actually happened in adults who were recently discharged from hospitalization for HF (HHF), according to the LINK-HF* study.
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.